{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:39:14Z","timestamp":1776458354283,"version":"3.51.2"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.leukres.2012.02.032","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T15:32:37Z","timestamp":1332862357000},"page":"804-805","source":"Crossref","is-referenced-by-count":12,"title":["Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"36","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.02.032_bib0005","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2012.02.032_bib0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.02.032_bib0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2010.10.018","article-title":"Imatinib treatment in chronic myelogenous leukemia: what have we learned so far?","volume":"300","author":"Breccia","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2012.02.032_bib0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/pds.1259","article-title":"Assessing medication adherence from pharmacy records","volume":"15","author":"Steiner","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.leukres.2012.02.032_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00280102","article-title":"Measurement of patient compliance and the interpretation of randomized clinical trials","volume":"41","author":"Vander Stichele","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.leukres.2012.02.032_bib0030","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/00005650-199909000-00002","article-title":"Validation of patient reports, automated pharmacy records and pill count with electronic monitoring of adherence to antihypertensive therapy","volume":"37","author":"Choo","year":"1999","journal-title":"Med Care"},{"key":"10.1016\/j.leukres.2012.02.032_bib0035","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1200\/jco.2006.24.18_suppl.6119","article-title":"Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients on imatinib","volume":"24","author":"Tsang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.032_bib0040","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1200\/jco.2006.24.18_suppl.6038","article-title":"Compliance and persistency with imatinib","volume":"24","author":"Feng","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.032_bib0045","first-page":"22","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukemia","volume":"49","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.leukres.2012.02.032_bib0050","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1182\/blood.V110.11.5159.5159","article-title":"Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST","volume":"110","author":"Halpern","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.032_bib0055","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.032_bib0060","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.032_bib0065","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.032_bib0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"issue":"November","key":"10.1016\/j.leukres.2012.02.032_bib0075","article-title":"Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study","author":"J\u00f6nsson","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2012.02.032_bib0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007995.2011.649849","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"Yood","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.leukres.2012.02.032_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2012.01.021","article-title":"Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia","author":"Gater","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2012.02.032_bib0090","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-04-347575","article-title":"Investigating personal and treatment related factors associated with adherence behavior in patients with chronic myeloid leukemia receiving long term imatinib therapy","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T23:04:25Z","timestamp":1593903865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261200121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S014521261200121X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.02.032","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}